InvestorsHub Logo
Followers 4
Posts 1139
Boards Moderated 0
Alias Born 04/27/2006

Re: None

Friday, 09/30/2016 2:23:37 PM

Friday, September 30, 2016 2:23:37 PM

Post# of 8484
Recruiting Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Conditions:
Pancreatic Cancer; Advanced Pancreatic Ductal Adenocarcinoma

Interventions:
Drug: Gemcitabine; Drug: Nab-paclitaxel; Drug: PEGPH20

Phase:


Sponsor/Collaborators:
Memorial Sloan Kettering Cancer Center; Halozyme Therapeutics

Study Start:
July 2016

Primary Completion:
July 2019

First Received:
September 29, 2016

Last Updated:
September 29, 2016

Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News